Doxycycline

Generic Name
Doxycycline
Brand Names
Acticlate, Adoxa, Apprilon, Atridox, Doryx, Doxy, Doxycin, Lymepak, Mondoxyne, Monodox, Morgidox, Okebo, Oracea, Periostat, Targadox, Vibramycin
Drug Type
Small Molecule
Chemical Formula
C22H24N2O8
CAS Number
564-25-0
Unique Ingredient Identifier
334895S862
Background

Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is...

Indication

Doxycycline is indicated for the treatment of various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria, including:

It is also used to treat infections caused by the following gram-negative microorganisms:

Associated Conditions
Acinetobacter Infections, Anthrax, Bacterial Infection caused by Enterobacter aerogenes, Bartonellosis, Brucellosis, Campylobacter Infection, Chancroid, Chlamydia Trachomatis Infection, Early Lyme Disease, Granuloma Inguinale, Infection Due to Escherichia Coli, Inhalational Anthrax, Klebsiella Infections, Lymphogranuloma Venereum, Malaria caused by Plasmodium falciparum, Nongonococcal urethritis, Plague caused by Yersinia pestis, Psittacosis, Rectal infection caused by Chlamydia Trachomatis, Relapsing fever caused by Borrelia recurrentis, Respiratory Tract Infection Bacterial, Rickettsial infectious disorders, Severe Acne, Sexually Transmitted Infections (STIs), Shigella Infection, Trachoma inclusion conjunctivitis, Tularemia, Vibrio Cholerae Infection, Acute Intestinal amebiasis, Susceptible Bacterial Infections, Uncomplicated endocervical infection, Uncomplicated urethral infection
Associated Therapies
-
globenewswire.com
·

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Fortress Biotech announces FDA approval of Emrosi for rosacea and potential approval of cosibelimab for cSCC, with financial results for Q3 2024 showing a net loss of $15 million.
webmd.com
·

New Rosacea Treatment Option Approved by the FDA

FDA approves minocycline (Emrosi) for rosacea in adults, offering a new treatment option for pimple-like bumps. Emrosi, a once-daily oral capsule, reduces swelling and inflammation with extended-release technology. Available in the U.S. by late 2024 or early 2025, it was found more effective than current standard care and placebo in clinical trials. Common side effects include indigestion, and caution is advised for sun exposure, pregnancy, and children under 8.
pharmaphorum.com
·

Journey slips on FDA approval of rosacea therapy

Journey Medical's Emrosi, a new minocycline hydrochloride capsule, has received FDA approval for treating rosacea's inflammatory lesions in adults. Despite concerns over the lack of a redness reduction claim and competition from generic Oracea, Journey's CEO Claude Maraoui anticipates Emrosi's strong market position and potential $300 million annual sales, with a launch planned for Q1-Q2 2025.
healio.com
·

'Another arrow to the quiver for physicians': FDA approves Emrosi for rosacea

FDA approves Emrosi, a 40 mg minocycline hydrochloride extended release capsule, for rosacea treatment in adults, supported by two phase 3 trials showing superiority over placebo and Oracea.
quantisnow.com
·

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline)

Journey Medical announces FDA approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for treating rosacea in adults, developed with Dr. Reddy's Laboratories Ltd. Emrosi demonstrated superiority over standard-of-care and placebo in Phase 3 trials, with initial U.S. market supply expected in Q1 or Q2 2025.
dermatologytimes.com
·

FDA Approves Journey Medical's DFD-29 for Rosacea

Journey Medical Corporation announced FDA approval of minocycline hydrochloride, 40 mg extended release capsules (Emrosi) for treating erythema and inflammatory lesions in rosacea patients. Supported by positive phase 3 trial data, Emrosi demonstrated efficacy and tolerability, with no significant adverse effects, positioning it as a best-in-class oral therapy for rosacea symptoms. The drug is expected to be available in Q1 or Q2 2025.
biospace.com
·

FDA Action Alert: Journey, Merus, PTC and Autolus

FDA to decide on Journey's rosacea drug DFD-29, Merus' bispecific antibody for NSCLC and PDAC, PTC's gene therapy Upstaza for AADC deficiency, and Autolus' CAR T therapy obe-cel for ALL by November 4, 6, 13, and 16 respectively.
© Copyright 2024. All Rights Reserved by MedPath